Medical

RICHMOND, Calif., Jan. 8, 2014 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo’s president and chief executive officer, will present an update on Sangamo’s clinical and preclinical ZFP Therapeutic® programs and upcoming milestones, as well as an overview of the Company’s business strategy at the 32ND AnnualJ.P. Morgan Healthcare Conference on Thursday, January 16TH at 11:00 am PT in San Francisco. “Sangamo […]

January 8, 2014 – AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. This platform […]

EMERYVILLE, CA and INGELHEIM, Germany, 7 January – Crystal Bioscience Inc. (Crystal) and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the discovery and development of therapeutic antibodies. Crystal Bioscience will apply its proprietary gel encapsulated microenvironment (GEM) and chicken immunization platforms to discover antibodies to multiple targets selected by […]

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 6, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young CBE, Executive Vice President, Commercial Operations, has informed the company of his decision to retire, effective February 4th. Mr. Young will continue to work directly with Gilead’s management team as a senior advisor. Mr. Young joined Gilead in 2004 to lead the company’s global commercial […]

NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it will provide an update on the progress of its clinical development programs after theNASDAQ Market closes on January 9, 2014. This update will […]

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that Rakesh Bamzai has joined the company and has been appointed president, India Commercial and Emerging Markets. Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, […]